Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Summit Therapeutics said that it had highlighted the potential of its pre-clinical new class antibiotic to treat all gonorrhoea, including multi-drug resistant strains, at the STI & HIV World Congress in Vancouver, Canada.
'The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease,' said R&D president David Roblin
'As shown by the pre-clinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains.'
'Further, there is a clear need for new gonorrhoea treatment options that would allow ceftriaxone to be reserved for the multitude of other serious infections that rely on its potency.'
At 1:08pm: (LON:SUMM) Summit Therapeutics PLC share price was +0.25p at 24.25p